Atorvastatin Pleiotropic Effects Mediated Via Suppression of TNF-α in Congestive Heart Failure Patients with Initial Normal TNF-α Levels

Journal of Heart and Lung Transplantation

Volumn 28, Issue 1, 2009, Pages 114-115

  Kotyla, Przemyslaw J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, ANIMAL; PYRROLES; REFERENCE VALUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149174239     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.04.007     Document Type: Letter

References (4)

1. Castro P., Miranda R., Verdejo H., et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant 27 (2008) 435-441
2. Kotyla P., and Sliwinska-Kotyla B. Therapeutic potential of HMG-CoA reductase inhibitors (statins) in systemic lupus erythematosus. In: Stevard T.I. (Ed). Progress in systemic lupus erythematosus research (2008), Nova Science, New York 227-243
3. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE?. The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86 (2002) 123-130
4. Kotyla P.J. Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial. Rheumatology 47 (2008) 381-382